Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims Orlistat promotes weight loss in overweight and obese patients with Type 2 diabetes receiving hypoglycaemic treatment, but has not been investigated in patients with newly diagnosed and previously untreated Type 2 diabetes. We evaluated the efficacy of 24 weeks’ treatment with orlistat, combined with a mildly reduced‐calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes. Methods A total of 249 Chinese patients (body mass index 25–40 kg/m 2) with recently diagnosed Type 2 diabetes were randomized to placebo (n = 124) or orlistat 120 mg (n = 125) three times daily; all patients followed a mildly reduced‐calorie diet. Patients had HbA 1c 6.5–8.5% (mean 7.3%) and had never received any glucose‐lowering medication. Results Orlistat‐treated patients achieved significantly greater weight loss at the study end than placebo‐treated patients (−5.4 vs. −2.4 kg; P < 0.0001). More orlistat than placebo patients lost ≥ 5% (60.5 vs. 26.8%; P < 0.0001) and ≥ 10% of their body weight (20.2 vs. 4.9%; P = 0.0002). A significantly greater decrease in HbA 1c from baseline was obtained with orlistat than placebo (−1.0 vs. −0.6%; P = 0.0008). Orlistat‐treated patients achieved a significantly greater decrease in fasting plasma glucose (−1.3 vs. −0.5 mmol/l; P = 0.0003) and in the 2‐h oral glucose tolerance test (−4.1 vs. −1.4 mmol/l; P < 0.0001) than placebo recipients. Also, more orlistat‐ than placebo‐treated patients improved from diabetic status to normal or impaired glucose tolerance (44.3 vs. 32.5%; P = 0.0763) after 24 weeks. Orlistat also produced improvements in lipid profiles and waist circumference. Conclusions In combination with a mildly reduced‐calorie diet, orlistat significantly reduces body weight, and improves glycaemic control and several cardiovascular risk factors in overweight and obese Chinese patients with newly diagnosed Type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Long-term Effects of Modest Weight Loss in Type II Diabetic Patients
Wing, R. R. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370100063012 · Cited by 484
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Self-citationEffect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
Hanefeld, M., & Sachse, G. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00237.x · Cited by 151
Cited by
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Clinical management and treatment of obesity in China
Zeng, Q., Li, N., Pan, X.-F., Chen, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00047-4 · Cited by 269
Gummesson, A., Nyman, E., Knutsson, M., & Karpefors, M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12971 · Cited by 162
“medication at inclusion; only five of the studies recruited drug-naïve patients.(19,42,44,57,59) Twenty seven of the 53 studies disclosed sufficient information to allow categorization of study groups according to change from baseline in diabetes medication as either increase,”
ResultZhao, L., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., Wang, R., Yuan, Y., & Li, X. (2024) · JAMA · doi:10.1001/jama.2024.9217 · Cited by 132
Ardissino, M., Vincent, M., Hines, O., Amin, R., Eichhorn, C., Tang, A. R., Collins, P., Moussa, O., & Purkayastha, S. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa133 · Cited by 40
Metadata
- Authors
- Shi, Y. ‐., Pan, C. ‐., Hill, J., & Gao, Y.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2005-07-22
- Volume
- 22
- Issue
- 12
- Pages
- 1737-1743
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2143145348
- Cited by
- 38
- References
- 9
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01723.x
- The paper
- Shi, Y. ‐., Pan, C. ‐., Hill, J., & Gao, Y. (2005). Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01723.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.